ASH Meeting on Lymphoma Biology

The 2020 ASH Meeting on Lymphoma Biology has been canceled. ASH has decided to cancel the meeting as a precautionary measure in response to the COVID-19 outbreak in the U.S. and worldwide. The health and safety of our meeting attendees is ASH’s top priority.

ASH encourages those who had planned to submit abstracts for this meeting to instead submit for consideration to ASH’s Annual Meeting and Exposition, the premier event in malignant and non-malignant hematology. The abstract submission site will open on June 4, 2020.

The ASH Meeting on Lymphoma Biology was established in 2014 to address an unmet need in the lymphoma community: to serve as the only U.S.-based forum specifically focused on basic and translational science relevant to lymphoma and chronic lymphocytic leukemia. The central goal of the meeting is to bring together experts from around the world to discuss the latest lymphoma fundamental science, address current challenges in the field, establish the highest priorities for investigation, and develop novel therapeutics.

This ACCME-accredited meeting consists of didactic sessions, abstract presentations, interactive workshops, and panel discussions. One important aspect of the meeting is Continuing Conversations, which are informal, interactive discussions designed for meeting attendees to address issues relevant to the lymphoma community. View the 2020 program.

Through participation in this meeting, you will be able to:

Discuss cutting-edge lymphoma research in a relaxed, informal setting.
Present and hear newest unpublished results.
Learn about current challenges in the field and the next steps to address those challenges.
Establish collaborations with leading experts in academia and industry.
Discuss how collaborative efforts can help accelerate the development of new therapeutic strategies.
Interact with attendees and build your professional network.
Earn CME and MOC credits.

The previous meetings (in 2014, 2016, and 2018) attracted more than 240 professional attendees from 24 countries, including more 65 trainees, junior researchers, and medical students.

Who Should Attend?

Laboratory-based investigators
Translational investigators
Junior faculty and trainees
Life sciences and biopharmaceutical industry
Policy-makers and regulatory scientists
Practitioners and other health professionals interested in lymphoma science

Program Co-Chairs

Laura Pasqualucci, MD
Columbia University
Elias Campo, MD, PhD
University of Barcelona
Ralf Küppers, PhD
University of Duisburg-Essen

Steering Committee Members

Laura Pasqualucci, MD, Columbia University [Co-chair]
Elias Campo, MD, PhD, University of Barcelona [Co-chair]
Ralf Küppers, PhD, University of Duisburg-Essen [Co-chair]
Catherine Bollard, MD, MbChB, Children’s National Medical Center
Wing C. (John) Chan, MD, City of Hope Medical Center
Dan Landau, MD, PhD, New York City Genome Center
Ronald Levy, MD, Stanford University
Bertrand Nadel, PhD, French National Institute of Health and Medical Research
Margaret Shipp, MD, Dana Farber Cancer Institute
Louis Staudt, MD, PhD, National Cancer Institute
Christian Steidl, MD, British Columbia Cancer Agency
Karin Tarte, PharmD, PhD, University of Rennes
Margot Thome-Miazza, PhD, University of Lausanne

Explore the Meeting on Lymphoma Biology

Questions?

Please submit all general inquiries to [email protected]. For information about sponsoring and/or exhibiting at MLB, contact SPARGO, Inc. at 800-564-4220, 703-631-6200, or [email protected].

91��Ʒ

Meetings